Company Description
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases.
The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.
It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP.
The company is based in Providence, Rhode Island. Ocean Biomedical, Inc. operates as a subsidiary of Poseidon Bio, LLC.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Ms. Elizabeth Ng M.B.A. |
Contact Details
Address: 515 Madison Ave Suite 8078 New York, New York 10022 United States | |
| Phone | (646) 908-2658 |
| Website | oceanbiomedical.com |
Stock Details
| Ticker Symbol | OCEA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001869974 |
| CUSIP Number | 67644P105 |
| ISIN Number | US67644C1045 |
| Employer ID | 87-1309280 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Elizabeth Ng M.B.A. | Chief Executive Officer and Director |
| Dr. Inderjote Kathuria M.B.A., M.D. | Chief Strategy Officer |
| Dr. Chirinjeev Baboo Kathuria M.B.A., M.D. | Founder and Executive Chairman of the Board |
| Dr. Jack A. Elias M.D. | Founder, Chairman of Scientific Advisory Board and Independent Director |
| Dr. Jonathan Kurtis M.D., Ph.D. | Founder, Chairman of Scientific Advisory Board and Director |
| Jolie G. Kahn CPA, Esq. | Chief Financial Officer |
| Robert John Sweeney | Chief Accounting Officer and Assistant Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2024 | 10-Q | Quarterly Report |
| Apr 15, 2024 | 10-Q/A | [Amend] Quarterly report |
| Apr 15, 2024 | 10-Q/A | [Amend] Quarterly report |
| Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 8, 2024 | 8-K | Current Report |
| Mar 4, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |